Look behind the lecture: maintaining a STEDI reserve of novel antibiotics – the importance of expanded value assessment

Written by The Evidence Base
Decision science Health policy ISPOR Look behind the lecture Medical devices, pharmaceuticals and vaccines Stakeholder engagement

In this feature, Monika Schneider (Duke-Margolis Center for Health Policy, DC, USA) discusses her presentation from the International Society for Pharmacoeconomics and Outcomes Research's 2020 Virtual Annual Meeting (18–20 May) concerning how an expanded value assessment protocol for novel antibiotics may help incentivize greater drug development. Please could you introduce yourself and your organization? I am a Managing Associate at the Duke-Margolis Center for Health Policy (DC, USA). The mission of the center is to improve both overall health and the value of healthcare, through practical, innovative and evidence-based policy solutions. What are some of the challenges and limitations associated...

To view this content, please register now for access

It's completely free